MUVON Therapeutics was featured by Nature as one of the companies leading the way with innovative treatments for stress urinary incontinence, showcasing the immense potential in women's health advancements. Despite women driving 80% of healthcare spending, women's health receives less than 1% of biopharma funding. Deana Mohr, CEO of MUVON Therapeutics, highlights the issue: "Investors often see women’s health as a niche 'wellness' sector rather than an area of high unmet medi

MUVON's latest article was recently published in Leading Opinions Gynäkologie & Geburtshilfe, dealing with the topic of stress urinary...